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Abstract
Background—Patients in the neonatal intensive care unit (NICU) are at high risk for healthcare-
associated infections. Variability in reported infection rates among NICUs exists, possibly related 
to differences in prevention strategies. A better understanding of current prevention practices may 
help identify prevention gaps and areas for further research.
Methods—We surveyed infection control staff in NICUs reporting to the National Healthcare 
Safety Network (NHSN) to assess strategies used to prevent MRSA transmission and central-line 
associated bloodstream infections in NICUs.
Results—Staff from 162 of 342 NICUs responded (response rate 47.3%). Most (92.3%) NICUs 
use central-line insertion and maintenance bundles, but maintenance practices varied, including 
agents used for antisepsis and frequency of dressing changes. Forty-two percent reported routine 
screening for MRSA colonization upon admission for all patients. Chlorhexidine gluconate (CHG) 
use for central line care for at least one indication (central line insertion, dressing changes, or 
port/cap antisepsis) was reported in 82 NICUs (51.3%). Among sixty-five NICUs responding to 
questions on CHG use restrictions, 46.2% reported no restrictions.
Conclusions—Our survey illustrated heterogeneity of CLABSI and MRSA prevention practices 
and underscores the need for further research to define optimal strategies and evidence-based 
prevention recommendations for neonates.
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Healthcare-associated infections are an important cause of illness and death among infants, 
especially premature neonates. Central line-associated bloodstream infections (CLABSI) are 
the leading type of device-associated infections among patients in the neonatal intensive 
care unit (NICU) reported to the National Healthcare Safety Network.1 The incidence of 
CLABSI reported from NICUs is consistently among the highest reported when compared to 
other hospital locations.1 Methicillin-resistant Staphylococcus aureus (MRSA) infections 
remain a significant cause of HAIs among NICU patients.2,34 Evidence-based 
recommendations for preventing CLABSI and MRSA transmission, largely based on studies 
assessing preventability in adults, have been published.5,6 However, there are relatively few 
studies that evaluate the preventability of HAI in pediatric settings, and NICU-specific 
infection prevention studies are sparse. Consequently, variation in HAI prevention practices 
in NICUs is likely to exist and yet information about this variation is not currently available. 
This survey was aimed at garnering a better understanding of current NICU prevention 
practices and to describe variability in practices among US NICUs to identify areas where 
further research is needed.
Methods
Study Participants and Design
We identified NICUs that reported CLABSI data to the National Healthcare Safety Network 
(NHSN) from January 1 through December 31, 2009. In December 2010, NHSN-designated 
contacts at each identified facility were sent the survey using an online survey tool7 which 
delivered via email the link for the survey. The e-mail requested completion of the 
questionnaire by one member of the infection prevention team. Team members could work 
together to answer questions if necessary, and we asked for submission of only one survey 
per facility. Reminders were sent at two week intervals to non-responders until the close of 
the survey on February 18th, 2011. These activities were considered not to be human 
subjects research by the CDC’s Institutional Review Board and IRB approval to tie facility 
rates to the study was not granted.
Survey Instrument
The survey included questions regarding demographic information, strategies to prevent 
MRSA transmission, and CLABSI prevention practices. Published literature available at the 
time of survey design was reviewed to construct questions about prevention practices. It was 
piloted among Infection Preventionists (IP) and infectious disease physicians in six facilities 
via telephone to improve clarity, readability, and minimize response time. Revisions were 
made based on suggestions from the pilot group. The questionnaire was then entered in an 
online survey tool.7 Respondents were not required to answer all questions in order to 
advance through the survey. Supplementary data on responding hospitals were obtained 
from the NHSN Annual Facility Survey, which collects information including geographic 
location, facility type, medical school affiliation, and number of beds.
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Data analysis was performed in SAS 9.2 (Cary, NC). NHSN facility characteristics were 
merged with survey data. Those institutions that recorded an invalid NHSN organization 
identification were excluded. Respondents and non-respondents were compared using χ² 
analysis for facility type, region, and teaching affiliation. Median numbers of beds were 
compared using non-parametric testing (i.e. Kruskal-Wallis Test). A 2-tailed P value < 0.05 
was considered significant. Numbers of responses to each question were tallied, and 
frequencies of answer selections calculated. Percentages represent the selected answer 
choice divided by the numbers of NICUs that responded to the question.
Results
Characteristics of participating NICUs
The survey was distributed to 342 NICUs in 39 states. Responses were received from 162 
(47.3%) unique NICUs from 32 states; no duplicate surveys were received. Two NICUs 
were excluded because the facility identification numbers were not valid NHSN 
identification numbers. Table 1 displays facility characteristics of survey participants and 
non-responders gathered from the NHSN Annual Survey. Hospital type and region were 
similar among responders and non-responders, but responders tended to be larger facilities 
with teaching affiliations. The majority of participants reported their hospital role as an 
infection preventionist who routinely covers 1 or more NICUs (89/159, 56%); remaining 
participants reported their role as IP managers (62/159, 39%), hospital epidemiologist 
(2/159, 1%), or other (6/159, 4%).
Prevention of transmission of MRSA in NICUs
Survey participants were asked about practices in their NICU surrounding MRSA 
transmission prevention and decolonization. When asked about the importance of MRSA, 
78.2% (111/142) reported that MRSA has not been an important, endemic cause of 
healthcare-associated infections in their NICU; 19% (27/142) reported that while MRSA is 
not a significant cause of HAIs, they have experienced at least one cluster or outbreak of 
MRSA in the previous 12 months. The majority of NICUs reported routine screening for 
MRSA colonization upon admission, but most did not conduct point prevalence screening 
(Table 2). Of note, 41% (58/141) reported that their state mandates MRSA reporting or 
screening. For patients found to be colonized or infected with MRSA, almost all (98.6%) 
instituted Contact Precautions, and the majority either placed these patients in a private 
room or a designated area with other MRSA-positive patients (Table 2). Cohorting of 
nursing staff to only MRSA positive patients was reported by 38.7% of NICUs (Table 2).
For the 132 facilities that reported ever screening patients for MRSA, the most commonly 
reported anatomical site of screening was the nose 93.2 % (n=123), followed by umbilicus 
26.5% (n=35), axillae 25% (n=33), and groin 22% (n=29). The screening methods reported 
also varied widely, and included PCR/DNA based screening, standard culture methods, or 
rapid culture (MRSA selective media) methods; these methods were evenly dispersed 
among NICUs. One-third of surveyed NICUs reported ever attempting to decolonize NICU 
patients colonized or infected with MRSA (Table 3). Among the 44 NICUs that reported 
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mupirocin use for decolonization, 22 (50%) did not have any restrictions on weight, 
gestational age, or chronological age prior to use, and 42 (95%) reported the intranasal site 
as the most common site of application. Use of chlorhexidine gluconate (CHG) baths for 
decolonization was less common (7/48, 14.6%).
Prevention of central line-associated bloodstream infections
The majority of NICUs reported use of central line insertion and maintenance bundles. The 
key components of insertion bundles were generally consistent across NICUs. Selected 
questions concerning CLABSI prevention practices are shown in Table 4. The majority of 
NICUs reported that education and training programs were available for staff who insert 
central lines (Table 4).Maximal barrier precautions for insertion of central lines were 
reported to be used by 98.5% of NICUs, but when asked specifically about drape type, 13.5 
% (19/141) reported using drapes that cover the insertion site only. The most common 
reasons for central line use reported by 145 NICUs were: total parenteral nutrition 
administration (95.2%), administration of intermittent medications (93.8%), administration 
of blood products (69%), collection of blood cultures (51%), and collection of blood for 
laboratory tests other than culture (51%). Duration of umbilical catheter use was limited by 
69.3% (97/140) of NICUs. The most common use duration limits reported by 94 NICUs 
were: 6–10 days in 63.5%, 11–15 days in 19.2%, 1–5 days in 12.8%, and 16–21 days in 
3.2%. Duration of use was not limited at all for peripherally inserted central catheters 
(PICC) in 85.8% (121/141) of NICUs; for those that reported a limitation on duration of 
PICC line use, 75% (15/20) reported a timeframe less than 6 weeks.
Use of maintenance bundles was reported by 65.0% of NICUs, and the need for a central 
line was assessed daily in nearly all (Table 4). Hand hygiene was performed before 
accessing a central venous catheter “often” (i.e. approximately 75% of the time) by 25.2% of 
NICUs and “always” (i.e. approximately 100% of the time) by 73.4% of NICUs. The 
frequency of catheter site dressing changes varied, with 54 % reporting changes only if 
visibly soiled, damp, or if a non-occlusive dressing; 46% report changes on a specific 
schedule. For those centers using schedules, transparent dressings were changed every 3–7 
days by 71.9% (49/64) and gauze dressings were changed within 3 days by 63.6%, (28/44).
The use of CHG and other antiseptics for practices including central line insertion, dressing 
changes, and port/cap antisepsis is shown in Table 5. Povidone iodine was used most often 
(63.4%) for catheter-site dressing changes, and alcohol swabs were used most often (74.7%) 
for catheter port/cap antisepsis. CHG use for at least one indication (i.e. central line 
insertion, dressing changes, or port/cap antisepsis) was reported in 51.3% (82/160). Nine 
NICUs that reported use of CHG for central line insertion did not respond to questions 
surrounding restrictions. When asked about restrictions (e.g., chronological or gestational 
age, birth weight) on CHG use for central line insertion, 46.2% (30/65) NICUs reported no 
restriction on use. Among the 65 NICUs that reported restrictions on use for central line 
insertion, the most frequent gestational age restriction was 28 weeks (20, 30.8%), the most 
frequent chronological age restriction was 8 weeks (6, 9.2%), and the most common birth 
weight restriction was 1,000 grams (9, 13.8%). Seventeen NICUs (26.2%) reported using 
gestational age alone as a restricting factor; four reported using birth weight alone and four 
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reported using chronological age alone. Ten NICUs reported a combination of at least two of 
these factors in restrictions. Restrictions on CHG use for dressing changes and port/cap 
antisepsis were similar to the restrictions reported above.
Discussion
As the largest survey to date of NICU practices and policies surrounding HAI prevention 
strategies, this survey illustrates the heterogeneity of practices nationally and helps direct 
future lines of research. The findings in this survey are generally consistent with smaller 
previously published NICU HAI prevention strategy surveys,8–11 but offer a broader 
perspective on the variability of these practices across a range of facility types. The 
responses are representative of those NICUs that report to NHSN, and comprise a wide 
geographic distribution as well as diverse facility types and sizes. Nearly one quarter had no 
teaching affiliation, and individual unit bed size varied widely; in contrast, other studies 
have garnered responses from only medical school-affiliated centers or did not offer details 
regarding unit size. Hence, this survey likely provides a more representative description of 
practices than other previous efforts and points to the need for studies that can provide 
evidence for best practices in areas including MRSA prevention strategies, components of 
central line maintenance bundles, use of CHG in central line maintenance, and strategies to 
assure appropriate central line access (e.g., restricting central line access for blood draws).
MRSA central line-associated bloodstream infections have been declining in adult intensive 
care settings12 but remain problematic in NICUs.2–4 In accordance with CDC guidance on 
the control of multi-drug resistant organisms in healthcare settings,13 the practice of almost 
all NICUs was to place patients in Contact Precautions when MRSA infection or 
colonization was identified. Although MRSA screening is not routinely recommended, our 
survey found that 41.5% of NICUs were routinely screening patients on admission. This is 
lower than the 65% reported in a previous survey.10 This difference may be related to 
variation in responses from states that mandate MRSA screening. Variability was noted in 
screening mechanisms (both body site screened and testing method used) and decolonization 
protocols. Among those NICUs that attempt to decolonize patients, most often the physician 
determines which patients are decolonized, and standardized decolonization protocols were 
uncommon. Despite the fact that mupirocin has not been approved by the U.S. Food and 
Drug Administration (FDA) for use in children less than 12 years-old, mupirocin use for 
MRSA decolonization was reported by 44 facilities surveyed. These results highlight the 
need for controlled studies in NICU settings addressing the effectiveness of MRSA 
screening in preventing MRSA HAIs, and establishing optimal screening procedures and 
decolonization protocols, so that evidence-based recommendations can be established.
While pediatric studies of central-line care bundles have demonstrated an impact in CLABSI 
rate reduction, these evaluations have often included both insertion and maintenance bundles 
without individual assessment of each bundle component.14–19 In our survey, nearly all 
NICUs reported use of insertion bundles while fewer reported use of and maintenance 
bundles for central lines. Recent studies have demonstrated the importance and impact of 
implementing maintenance bundles on CLABSI reduction in pediatric patients.15 The 
composition of the maintenance bundles varied among the NICUs participating in our 
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current survey. For example, practices surrounding dressing changes vary with some centers 
only changing dressings if soiled and others adhering to a schedule; CDC guidelines 
recommend changing dressings when soiled, but routine schedules based on dressing type 
are also prescribed for changing dressing even if not soiled.5 The guidelines do offer a 
caveat for infants when “the risk for dislodging the catheter may outweigh the benefit of 
changing the dressing”;5 hence, centers may be choosing to change dressings on a less 
frequent schedule given risk and/or difficulty of replacing an inadvertently dislodged 
catheter. CDC recommendations for bundle implementation state that the components of the 
bundle should be both evidence based and cost-effective,5 which can prove difficult in 
NICU patients given the paucity of evidence for some practices; hence, further studies 
surrounding appropriate maintenance practices for central-lines in NICU patients are 
needed.
Greater than half of all participating NICUs reported using CHG for at least one of the 
following indications: central line insertion, dressing changes, or port/cap antisepsis. While 
CHG is a recommended component of adult central line insertion and maintenance practices, 
there is no recommendation for its use in infants less than 2 months of age.5 The FDA 
recently changed the labeling of CHG products to state “use with care in premature infants 
or infants under 2 months of age. These products may cause irritation or burns”.20 Despite 
these issues, practice surveys in addition to ours have confirmed its use in patients with a 
broad range of chronological ages, gestational ages, and birth weights.9 In our survey, 50% 
of NICUs reported using CHG for central line insertion or maintenance, and only six of 
these reported restriction of its use to infants over 2 months of age. Furthermore, we found 
that restrictions ranged widely from no restriction to restrictions that used a combination of 
all three of the aforementioned factors. These data may indicate that community practices 
have advanced in the absence of evidence based recommendations. This may be reflective of 
the restriction of the recommendation process when applied to pediatric populations where 
adequately powered randomized-controlled trials may be lacking.
It has been suggested that pediatric patients’ central lines are accessed and used differently 
than those in adult patients (i.e., lines are maintained for a longer duration and more 
frequently used for blood draws). This survey provides information regarding the reasons for 
and frequency of central line access in NICU patients. Perhaps most concerning, half of 
NICUs reported using central lines to obtain blood samples for routine laboratory testing. 
Frequent central line manipulation has been suggested as a possible risk for CLABSI.21,22 
Blood coating the internal catheter surface and needless connectors may directly increase the 
likelihood of biofilm formation leading to infection.23 A prospective cohort study carried 
out among NICU patients demonstrated that the risk for CLABSI increased with increasing 
number of blood samples taken through the central line.22 Central lines are likely used for 
blood collection to minimize painful peripheral blood draws in the neonate, and any 
intervention aimed at limiting this practice must consider this. In depth examination of the 
reasons that central lines are accessed, the appropriateness of line access, the necessity of the 
laboratory testing, and potential strategies to minimize central line access are warranted.
There were several limitations to this survey. Participants may have been inclined to report 
what they perceived to be correct or desired responses, as opposed to true practices. 
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However, the anonymity of the electronic format of this survey may have limited this effect, 
as has been suggested elsewhere.24 Because we were unable to link responding facilities to 
their reported NHSN infection rates, we could not determine whether reported rates of 
MRSA infections were indeed lower in the facilities that reported that MRSA was not an 
important, endemic cause of HAIs in their NICUs. The overall response rate was 47.3%, 
which is remarkable given the amount of clinical detail requested from responders. While 
respondents could have differed from non-respondents in terms of their strategies for 
prevention of MRSA infections and CLABSIs, this would not change the conclusion that 
there is a great deal of variability in these practices. Finally, while responders were more 
likely to be larger facilities with a teaching affiliation, there was wide geographic 
representation with smaller, non-teaching hospitals representing 22% of respondents; hence, 
these results are informative regarding practices in a wide array of NICU types.
Conclusion
Encouragingly, in areas where published recommendations are available, most reported 
practices were in accordance with these recommendations; these include such practices as 
using Contact Precautions for patients with MRSA, assessing the need of a central-line daily 
for removal when not necessary, performance of hand hygiene prior to central-line use, 
education for all people inserting central-lines, and use of maximal barrier precautions when 
inserting a central-line. Reported practices surrounding MRSA screening and decolonization 
as well as chlorhexidine use for central line insertion and maintenance demonstrated the 
greatest variability. This variability is likely related to the paucity of pediatric-specific 
recommendations which is secondary to, not only, the lack of pediatric studies, but the 
increasing standard for evidence prior to recommendation development. This is especially 
important in pediatric populations where smaller numbers of impacted patients, parental 
concern, or other factors may impact the ability of researchers to reach adequate sample 
size. Consideration must also be given to the appropriateness of evidence derived from adult 
studies and in what areas is it essential to have pediatric specific studies prior to developing 
recommendations. Hence, uniformity of practice and implementation of potentially better 
practices is sacrificed for higher standards of evidence, but may be achievable if alternative 
standards for recommendation development are considered.
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Table 1
Characteristics of NICU facilities of survey participants compared with non-responders
Characteristic Participants (n=160) Non-responders (n=182) p-value χ²*
Facility Type n (%) 0.19
  General Hospital 139 (86.9) 168 (92.3)
  Children’s Hospital 14 (8.7) 11 (6)
  Other 7 (4.4) 3 (1.7)
Teaching affiliation n (%) 0.03
  Yes 124 (77.5) 122 (67)
  No 36 (22.5) 60 (33)
Region n (%) 0.55
  Northeast 65 (40.6) 63 (34.6)
  Midwest 26 (16.3) 28 (15.4)
  South 39 (24.4) 47 (25.8)
  West 30 (18.7) 44 (24.2)
Median Hospital bed size 392 (250–595) 338 (200–460) 0.03*
(IQR) Median NICU bed size (IQR) 30 (20–43.5) 20 (14–36) 0.0002*
*
NOTE: Wilcoxon rank-sum used to generate p-value for these columns
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Table 2
Selected practices for the prevention of MRSA transmission in NICUs of survey respondents
Question
No. of Respondents 
(%)
Does your facility screen NICU patients routinely on admission? (n=142)
  YES, all patients screened 59 (41.5)
  YES, but only selected patients (i.e. transfers) 48 (33.8)
  NO, but we will screen on admission during outbreaks/increased transmission 9 (6.4)
  NO, MRSA screening on admission is not done 26 (18.3)
Does your facility routinely perform point prevalence testing for MRSA among NICU patients? (n=141)
  YES 49 (34.8)
  NO 91 (64.5)
  Don’t know 1 (0.7)
In your NICU, which of the following actions are taken for patients found to be infected or colonized with 
MRSA? (n= 142)
  Contact precautions initiated 140 (98.6)
  Sign posted outside room/cohorted area describing the isolation precautions 124 (87.3)
  Visitors required to wear personal protective equipment 99 (69.7)
  Patient placed in private room if available 94 (66.2)
  Patient placed in designated room or area with other MRSA positive patients 90 (63.4)
Does your NICU EVER designate specific nursing staff to only MRSA positive or only MRSA negative 
patients? (n=142)
  YES 55 (38.7)
  NO 82 (57.8)
  Don’t know 5 (3.5)













Hocevar et al. Page 12
Table 3
Reported practices in NICUs of survey respondents for decolonization of patients colonized or infected with 
MRSA
Question No. of Respondents (%)
Does your NICU ever attempt to decolonize patients colonized or infected with MRSA? (n=142)
  YES 48 (33.8)
  NO 88 (62.0)
  Don’t know 6 (4.2)
Which Patients are decolonized? (n=48)
  All MRSA positive patients 15 (31.3)
  All MRSA positive patients who meet certain clinical requirements (stability, gestational age/weight) 2 (4.2)
  Some patients but determined by clinician 25 (52.0)
  Only during outbreak situations 2 (4.2)
  Never or rarely done 4 (8.3)
Does your facility have a standard regimen for MRSA decolonization? (n=48)
  YES 27 (56.2)
  NO 21 (43.8)
Do you use mupirocin for decolonization? (n=48)
  YES 44 (91.7)
  NO 3 (6.3)
  Don’t know 1 (2.0)
Do you use Chlorhexidine baths in your NICU for MRSA decolonization? (n=48)
  YES 7 (14.6)
  NO 40 (83.3)
  Don’t Know 1 (2.1)
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Table 4
Selected practices in NICUs of survey respondents for the prevention of central line–associated bloodstream 
infections
Question No. of Respondents (%)
Does your NICU have an education or training program for staff responsible for insertion of central lines?
  YES 130 (91.5)
  NO 12 (8.5)
Does your NICU use central line catheter BUNDLES for INSERTION of central lines in neonates?
  YES 131 (92.3)
  NO 11 (7.7)
What components are included in your NICU central line insertion bundle? (n=131)
  Insertion checklist 113 (86.3)
  Packaged trays, carts, or boxes that include full sterile barriers 120 (91.6)
  Hand hygiene 128 (97.7)
  Maximal barrier precautions 129 (98.5)
  Skin antisepsis 129 (98.5)
  Staff are empowered to stop a non-emergent procedures if it does not follow sterile insertion practices 126 (96.2)
  Conduct insertion training for all care providers (including slides and videos) 87 (66.4)
Does your NICU use bundles for MAINTENANCE of central lines?
  YES 93 (65.0)
  NO 50 (35.0)
Are there daily assessments of the NICU patient’s need for a central line? (e.g. during patient rounds)
  YES 129 (97)
  NO 4 (3)
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Table 5
Selected uses for chlorhexidine and other antiseptics in NICUs of survey respondents for management of 
central line insertion and maintenance









Chlorhexidine gluconate 74 (51.0) 66 (46.5) 33 (22.6)
Povidone iodine 105 (72.4) 90 (63.4) 9 (6.2)
70% isopropyl alcohol/alcohol swabs 41 (28.3) 47 (33.0) 109 (74.7)
Other* 0 3 (2.1) 3 (2.1)
*
included normal saline, ‘nothing used’
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